肿瘤浸润免疫细胞谱及其变化与 HER2 阳性胃癌患者术前化疗中加用曲妥珠单抗相关

Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive

曲妥珠单抗的加入调节了免疫微环境，提示了抗HER2治疗良好结局的潜在机制，并为可切除HER2(+) GC患者的联合免疫治疗提供了理论依据。